Shots:

• Hybridize to receive an up front & ~$114.26M upon achievement of development, regulatory & commercial milestones & is also eligible to receive royalties on net sales. The companies collaborated to develop BKV-targeting therapy & the trial is expected to initiate within 2yrs.
• AiCuris to get exclusive rights to develop & commercialize Hybridize's BKV program for BK virus-mediated nephropathy in renal transplant patients
• The collaboration will strengthen AiCuris’ anti-infective pipeline & accelerate the program to patients suffering from BKV-associated nephropathy. Additionally, Pritelivir is currently in the P-III program for acyclovir-resistant mucocutaneous HSV infections

Ref: Accesswire | Image: AiCuris